{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:07:00Z","timestamp":1790996820961,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":186,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ajhg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Human Genetics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ajhg.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T11:44:02Z","timestamp":1552563842000},"page":"625-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates"],"prefix":"10.1016","volume":"104","author":[{"given":"Xuling","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becca","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Presnyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Frassetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Milton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry E.","family":"Benenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Sabnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Besin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Lukacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin T.","family":"Guey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick F.","family":"Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo G.V.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajhg.2019.02.003_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ymgme.2006.11.008","article-title":"Cellular and tissue distribution of intravenously administered agalsidase alfa","volume":"90","author":"Murray","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib2","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajhg.2019.02.003_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ajhg.2019.02.003_bib4","doi-asserted-by":"crossref","first-page":"e0144958","DOI":"10.1371\/journal.pone.0144958","article-title":"Distributions of globotriaosylceramide isoforms, and globotriaosylsphingosine and its analogues in an \u03b1-galactosidase A knockout mouse, a model of Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajhg.2019.02.003_bib5","doi-asserted-by":"crossref","first-page":"e0127048","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of Lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ajhg.2019.02.003_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ajhg.2019.02.003_bib7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","article-title":"Fabry disease under enzyme replacement therapy-new insights in efficacy of\u00a0different dosages","volume":"33","author":"Kr\u00e4mer","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ajhg.2019.02.003_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.retram.2016.09.001","article-title":"Fabry disease: A fundamental genetic modifier of cardiac function","volume":"65","author":"Tadevosyan","year":"2017","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.ajhg.2019.02.003_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12574-017-0340-x","article-title":"Fabry disease","volume":"15","author":"Yuasa","year":"2017","journal-title":"J.\u00a0Echocardiogr."},{"key":"10.1016\/j.ajhg.2019.02.003_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ajhg.2019.02.003_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease - current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genomics"},{"key":"10.1016\/j.ajhg.2019.02.003_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jgf2.76","article-title":"Fabry disease and its cardiac involvement","volume":"18","author":"Kubo","year":"2017","journal-title":"J.\u00a0Gen. Fam. Med."},{"key":"10.1016\/j.ajhg.2019.02.003_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ajhg.2019.02.003_bib14","doi-asserted-by":"crossref","first-page":"e99171","DOI":"10.1172\/jci.insight.99171","article-title":"Neuropathic pain in a Fabry disease rat model","volume":"3","author":"Miller","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajhg.2019.02.003_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymgme.2016.05.015","article-title":"Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass Spectrometry","volume":"118","author":"Elliott","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.02.003_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.ajhg.2019.02.003_bib18","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ymgme.2012.11.109","article-title":"Evaluation of long-term enzyme replacement therapy for children with Fabry disease","volume":"108","author":"Hebert","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib19","doi-asserted-by":"crossref","first-page":"282487","DOI":"10.1155\/2013\/282487","article-title":"Long-term effect of enzyme replacement therapy with fabry disease","volume":"2013","author":"Komori","year":"2013","journal-title":"Int. J. Otolaryngol."},{"key":"10.1016\/j.ajhg.2019.02.003_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11547-011-0710-9","article-title":"Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy","volume":"117","author":"Messalli","year":"2012","journal-title":"Radiol. Med. (Torino)"},{"key":"10.1016\/j.ajhg.2019.02.003_bib21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ajhg.2019.02.003_bib22","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.hoc.2017.05.002","article-title":"Therapeutic gene editing safety and specificity","volume":"31","author":"Lux","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ajhg.2019.02.003_bib23","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1111\/febs.13760","article-title":"Off-target effects of engineered nucleases","volume":"283","author":"Yee","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ajhg.2019.02.003_bib24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ajhg.2019.02.003_bib25","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ajhg.2019.02.003_bib26","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41591-018-0199-z","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajhg.2019.02.003_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.ajpath.2014.11.004","article-title":"\u03b1-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease","volume":"185","author":"Bangari","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ajhg.2019.02.003_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine mediated protection against Zika virus-induced congenital disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ajhg.2019.02.003_bib29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ajhg.2019.02.003_bib30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.108.149054","article-title":"Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease","volume":"328","author":"Ishii","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib32","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/ac203433e","article-title":"Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics","volume":"84","author":"Auray-Blais","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ajhg.2019.02.003_bib33","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.ymgme.2016.11.160","article-title":"Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model results in continuous supra-physiological enzyme activity and effective substrate reduction","volume":"120","author":"Huston","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","article-title":"Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase A efficiently corrects enzyme deficiency in Fabry mice","volume":"39","author":"Shen","year":"2016","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ajhg.2019.02.003_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","article-title":"Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease","volume":"114","author":"Kizhner","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human \u03b1-Galactosidase A with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib37","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of \u03b1-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1089\/10430349950017671","article-title":"Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer","volume":"10","author":"Ziegler","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.02.003_bib41","first-page":"195","article-title":"Fabry disease and the heart. Best Pract. Res. Clin. Endocrinol","volume":"29","author":"Seydelmann","year":"2014","journal-title":"Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","article-title":"The kidney in Fabry\u2019s disease","volume":"86","author":"Pisani","year":"2014","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ajhg.2019.02.003_bib43","article-title":"The kidney in Fabry disease: more than mere sphingolipids overload","volume":"Screening 4","author":"Trimarchi","year":"2016","journal-title":"J.\u00a0Inborn Errors Metab."},{"key":"10.1016\/j.ajhg.2019.02.003_bib44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ajhg.2019.02.003_bib45","doi-asserted-by":"crossref","first-page":"i634","DOI":"10.1093\/ndt\/gfy146.FP805","article-title":"Progression of nephropathy in Fabry patients receiving enzyme replacement therapy (ERT); relation to anti-drug antibody (ADA) status and proteinuria","volume":"33","author":"Warnock","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ajhg.2019.02.003_bib46","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human \u03b1-galactosidase A therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ajhg.2019.02.003_bib47","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/mt.2012.64","article-title":"Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD\/SCID\/Fabry mice","volume":"20","author":"Pacienza","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ajhg.2019.02.003_bib48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2119\/molmed.2009.00163","article-title":"Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice","volume":"16","author":"Higuchi","year":"2010","journal-title":"Mol. Med."},{"key":"10.1016\/j.ajhg.2019.02.003_bib49","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease","volume":"13","author":"Lee","year":"2003","journal-title":"Glycobiology"},{"key":"10.1016\/j.ajhg.2019.02.003_bib50","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.119.5.1137","article-title":"Overexpression of human alpha-galactosidase A results in its intracellular aggregation, crystallization in lysosomes, and selective secretion","volume":"119","author":"Ioannou","year":"1992","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ajhg.2019.02.003_bib51","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1083\/jcb.98.1.246","article-title":"Hydrolase secretion is\u00a0a\u00a0consequence of membrane recycling","volume":"98","author":"Hohman","year":"1984","journal-title":"J.\u00a0Cell Biol."}],"container-title":["The American Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929719300485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002929719300485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T20:54:45Z","timestamp":1570136085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002929719300485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0002929719300485"],"URL":"https:\/\/doi.org\/10.1016\/j.ajhg.2019.02.003","relation":{},"ISSN":["0002-9297"],"issn-type":[{"value":"0002-9297","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Human Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajhg.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society of Human Genetics.","name":"copyright","label":"Copyright"}]}}